GLP-1 Drugs Won't Work Unless You Fix This First

Why Your GLP-1 Isn't Working: The Foundation You Skipped

If you're taking a weight loss GLP-1 type or an appetite suppressant type drug, leading with the question, how quickly can I feel the weight loss or how quickly can I get these results is definitely the wrong question.

I know you paid real money for this. And I know what you were told it would do.

You're gonna see these amazing results that you're looking for, but understand that the way that these things work is they're just making it easier for you to achieve the calorie deficit that's necessary to actually see the result, and that sentence covers the whole mechanism, with everything else being detail underneath it.

Walk the chain from the injection to the scale and you can see where the work sits. The drug binds receptors in your gut and your brain, which slows how fast food leaves your stomach and raises the signal that tells your hypothalamus you have had enough, and that signal reduces how much you eat across the day, so less food eaten turns into fewer calories in, and fewer calories in than you burn is what makes fat come off.

Notice that the drug only touches the first two links. It changes your appetite and your gut timing. It does not reach into the last link and decide your intake for you.

Researchers have this part of the appetite pathway mapped out pretty thoroughly by now, since GLP-1 receptor agonists act on both central pathways in the brain and peripheral pathways in the gut to reduce hunger and slow gastric emptying, and that combination is what produces the reduction in food intake (Moiz et al., 2025).

Like if you take Reddit True Tide and you still force feed yourself to the point where you're in the surplus of calories, you're not going to see any results.

None of this is hypothetical, and it happens with liquid calories, with grazing, with a smaller appetite spread across food that is calorie dense enough to make the smaller appetite irrelevant. The suppression is real and the surplus is still possible.

There is also a nutrient partitioning piece that gets talked about loosely. Tirzepatide's long acting activation of the GIP receptor changes how fat cells handle nutrients, shifting adipocyte metabolism rather than simply shrinking appetite (Regmi et al., 2024). Whether GIP or glucagon receptor activity meaningfully raises basal metabolic rate in humans is a separate question, and I cannot point you to a study that settles it, so treat that part as open.

Picture the drug working the way power steering works in a car, since the wheel turns much easier once it kicks in, but your hands still have to be on it and the road still has to be chosen, because power steering never once decides where the car ends up going.

The GLP-1 agonist is gonna help mitigate your appetite, and that smaller appetite is a budget, not a result, which means the order you spend it in ends up shaping everything that follows.

Protein needs to come first in that spending. If appetite is down forty percent, protein has to be defended deliberately or it gets crowded out by whatever is easiest to eat, and losing weight without protein and resistance training means a meaningful chunk of what leaves is muscle.

Resistance training comes right after that. Two to four sessions a week is enough to change what the weight loss is made of.

Then sleep, because short sleep raises hunger hormones and works directly against the thing you are paying the drug to do.

But at the end of the day, the responsibility still falls on you to consume protein, eat in a calorie deficit, exercise, sleep, optimize your hormones and take care of your body.

Here is what actually happens to people who skip this. The drug works, the weight comes off, and then they stop the drug, and appetite returns to a body that never learned a single new habit and now has less muscle than it started with.

References:

Moiz A, Filion KB, Tsoukas MA et al.. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. Am J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/39892489/

Zhao X, Wang M, Wen Z et al.. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021. https://pubmed.ncbi.nlm.nih.gov/34497589/

Regmi A, Aihara E, Christe ME et al.. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024. https://pubmed.ncbi.nlm.nih.gov/38878772/